The Potential of Narrow-Band Imaging as a Novel Light Source for Photodynamic Therapy for Superficial Cancers via Endoscopes

Abstract

Background: Photodynamic therapy (PDT) has advanced through the utilization of photosensitizers and specific-wavelength light (600 nm). However, the widespread adoption of PDT is still impeded by high equipment costs and stringent laser safety requirements. Porphyrins, crucial in PDT, have another absorbance peak of blue light (= 380 - 500 nm). This peak corresponds to the wavelength of narrow-band imaging (NBI) (= 390 - 445 nm), an image-enhancement technology integrated into endoscopes by Olympus Medical Systems. The study aimed to investigate the potential of widely adopted NBI as a PDT light source for superficial cancers via endoscopes.

Methods: Esophageal and biliary cancers were selected for investigation. Human esophageal cancer cell lines (KYSE30, KYSE70, KYSE170) and cholangiocarcinoma cell lines (HuCCT-1, KKU-213) were subjected to verteporfin-mediated PDT under NBI light (= 390 - 445 nm). Assessments included spectrometry, crystal violet staining, and fluorescein imaging of singlet oxygen generation and apoptosis.

Results: Verteporfin exhibited a peak (= 436 nm) consistent with the NBI spectrum, suggesting compatibility with NBI light. NBI light significantly inhibited the growth of esophageal and biliary cancer cells. The half-maximum effective concentration (EC₅₀) values (5 J/cm²) for KYSE30, KYSE70, KYSE170, HuCCT-1, and KKU-213 were calculated as 2.78 0.37µM, 1.76 1.20 µM, 0.77 0.16 µM, 0.65 0.18 µM, and 0.32 0.04 µM, respectively. Verteporfin accumulation in mitochondria, coupled with singlet oxygen generation and observed apoptotic changes, suggests effective PDT under NBI light.

Conclusions: NBI is a promising PDT light source for superficial cancers via endoscopes.

Gastroenterol Res. 2024;17(2):72-81
doi: https://doi.org/10.14740/gr1694